Shamburg News · 8-K filed Nov 16, 2026, 8:00 AM EST

Relmada Therapeutics Appoints Jørn Skibsted Jakobsen as Chief Development Officer

RLMD · RELMADA THERAPEUTICS, INC.

  • Leadership change
  • Reg FD disclosure
  • Materiality: medium

On November 16, 2026, Relmada Therapeutics, Inc. announced in a press release, furnished as Exhibit 99.1 under Item 7.01, the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will lead clinical development across the pipeline, including the planned Phase 3 SPECTRUM program for NDV-01. The filing does not state an effective date for the appointment.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 7.01, accession 0001213900-26-120144.

Written from the filing by Shamburg Markets. Figures are as reported by the company.